Up 37% Since August, Is It Safe to Buy UnitedHealth Group Stock Again?

UnitedHealth has staged a 37% rally since August—driven largely by a new Berkshire Hathaway stake—after losing nearly half its value over the prior 12 months; third-quarter revenue rose 12% year-over-year to $113.2 billion but net margin was weak at 2.1%. Management raised full-year EPS guidance to at least $14.90 (from $14.65) and is exiting certain Medicare Advantage markets to shore up profitability, even as the company faces a Department of Justice investigation into billing practices. Valuation has moved from roughly a P/E of 10 pre-rally to about 17 today, implying upside if cost and utilization trends improve, but material legal and operational headwinds leave the outlook cautious for near-term investors.

Analysis

Market structure: Berkshire’s BRK.B stake and a 37% rally since August have temporarily increased demand for UNH, attracting momentum and index flows; at a trailing P/E ~17 vs ~10 in mid-2023, value buyers are rotating in but passive/ETF ownership means any negative news can trigger outsized outflows. Competitors (HUM, CI, CVS) stand to gain pockets of market share where UNH exits Medicare Advantage; hospitals/providers gain short-term negotiating leverage if utilization stays elevated and pushes down managed-care margins (UNH net margin 2.1%).

Risk assessment: Near-term (days–weeks) the biggest risks are headline volatility from DOJ probe updates or Berkshire 13F changes; medium-term (3–12 months) CMS rate decisions and Medicare Advantage enrollment shifts can shave multiple points off margins; tail scenarios include a multi-billion dollar DOJ settlement (> $5B) or a sustained utilization surge that reduces EPS >10% (>$1.5 impact). Hidden dependencies: UNH’s margin recovery hinges on utilization normalization and successful exits from unprofitable MA markets—both are multi-quarter processes.

Trade implications: Tactical longs should be size-limited and hedged—buy UNH equity only on pullbacks toward a P/E of 15 (~20–25% downside from peak) or use a 6–12 month buy‑write/collar to cap downside; consider 6–12 month call spreads if willing to accept limited upside cost. Relative trades: long HUM or CI vs short UNH in markets where UNH exits MA can capture share shifts over 6–12 months; credit markets: monitor UNH bond spreads for stress signals (>75bp widening vs. IG median).

Contrarian angle: Consensus treats Berkshire’s buy as endorsement; it may be opportunistic and size-limited—market underestimates regulatory/legal tail risk and time-to-recover margins. Reaction may be underdone on downside: a DOJ settlement or adverse CMS ruling could reprice UNH back to mid-teens P/E or lower within 6–12 months, creating a binary risk/reward that favors hedged exposure rather than naked long positions.

Key Decisions for Investors

• Establish a hedged long in UNH (ticker UNH) equal to 2–3% of equity portfolio: buy shares on a pullback to P/E ≈15 or buy now and simultaneously purchase a 6‑month 10%‑OTM put (max loss = premium) to limit downside while retaining upside to next 2 earnings cycles.
• If bullish directional but want defined cost: buy a 9–12 month UNH 20%/40% call spread (e.g., buy 1x 15% ITM call, sell 1x 35% OTM call) sized to 1–2% portfolio to capture re‑rating without full equity exposure.
• Execute a pair trade: long HUM (Humana) and short UNH, dollar‑neutral, 1.5% each of portfolio to exploit MA market exits—hold 6–12 months and reassess after next CMS rate announcement (expected within ~3–6 months).
• Reduce unmanaged exposure to managed‑care ETFs by ~20–30% and reallocate into defensive healthcare services (e.g., PBMs, pharma services) until DOJ clears or UNH reports two consecutive quarters of margin improvement; if UNH credit spreads widen >75bp vs IG median, trim longs further.